This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 110/8/904    most recent 01.CIR.0000139333.83620.5Dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antzelevitch, C. Articles by Thomas, G. Search for Related Content PubMed PubMed Citation Articles by Antzelevitch, C. Articles by Thomas, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETANILIDE CALCIUM COMPOUNDS CALCIUM, ELEMENTAL POTASSIUM SODIUM Related Collections Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2004;110:904-910.)
© 2004 American Heart Association, Inc.

Original Articles

Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties

Charles Antzelevitch, PhD; Luiz Belardinelli, MD; Andrew C. Zygmunt, PhD; Alexander Burashnikov, PhD; José M. Di Diego, MD; Jeffrey M. Fish, DVM; Jonathan M. Cordeiro, PhD; George Thomas, PhD

From the Masonic Medical Research Laboratory, Utica, NY (C.A., A.C.Z., A.B., J.M.D., J.M.F., J.M.C., G.T.), and CV Therapeutics, Inc, Palo Alto, Calif (L.B.).

Correspondence to Dr Charles Antzelevitch, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501. E-mail ca{at}mmrl.edu

Received February 19, 2004; de novo received March 29, 2004; revision received May 12, 2004; accepted May 21, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Ranolazine is a novel antianginal agent capable of producing antiischemic effects at plasma concentrations of 2 to 6 µmol/L without reducing heart rate or blood pressure. The present study examines its electrophysiological effects in isolated canine ventricular myocytes, tissues, and arterially perfused left ventricular wedge preparations.

Methods and Results— Transmembrane action potentials (APs) from epicardial and midmyocardial (M) regions and a pseudo-ECG were recorded simultaneously from wedge preparations. APs were also recorded from epicardial and M tissues. Whole-cell currents were recorded from epicardial and M myocytes. Ranolazine inhibited I_Kr (IC₅₀=11.5 µmol/L), late I_Na, late I_Ca, peak I_Ca, and I_Na-Ca (IC₅₀=5.9, 50, 296, and 91 µmol/L, respectively) and I_Ks (17% at 30 µmol/L), but caused little or no inhibition of I_to or I_K1. In tissues and wedge preparations, ranolazine produced a concentration-dependent prolongation of AP duration of epicardial but abbreviation of that of M cells, leading to reduction or no change in transmural dispersion of repolarization (TDR). At [K⁺]_o=4 mmol/L, 10 µmol/L ranolazine prolonged QT interval by 20 ms but did not increase TDR. Extrasystolic activity and spontaneous torsade de pointes (TdP) were never observed, and stimulation-induced TdP could not be induced at any concentration of ranolazine, either in normal or low [K⁺]_o. Ranolazine (5 to 20 µmol/L) suppressed early afterdepolarizations (EADs) and reduced the increase in TDR induced by the selective I_Kr blocker d-sotalol.

Conclusions— Ranolazine produces ion channel effects similar to those observed after chronic amiodarone (reduced I_Kr, I_Ks, late I_Na, and I_Ca). The actions of ranolazine to suppress EADs and reduce TDR suggest that, in addition to its antianginal actions, the drug may possess antiarrhythmic activity.

Key Words: ischemia • ion channels • intervals • depolarization

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Ranolazine is the first of a new class of compounds shown to exert antianginal effects without causing significant bradycardia and/or lowering systemic blood pressure.^1–3 The drug has been shown to increase left ventricular function in animals with chronic heart failure,⁴ and 2 clinical trials (Monotherapy Assessment of Ranolazine In Stable Angina [MARISA] and Combination Assessment of Ranolazine In Stable Angina [CARISA]) have established its effectiveness as an antianginal agent.^1–3 Ranolazine is known to produce a modest prolongation of the QT interval, yet little is known about the electrophysiological actions of the drug.¹ The present study was designed to assess the electrophysiological effects of ranolazine in myocytes, tissues, and arterially perfused wedge preparations isolated from the canine left ventricle.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
See the online-only Data Supplement (listed with this article at http://www.circulationaha.org) for information about Methods.^5,6

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effect of Ranolazine on I_Kr, I_Ks, I_K1, I_to, Late I_Na, I_Ca, Late I_Ca, and I_Na-Ca
Figures 1 to 3 show the effect of ranolazine to inhibit I_Kr, late I_Na, I_Ca, late I_Ca, and I_Na-Ca in canine left ventricular (LV) myocytes (midmyocardial and epicardial cells). Ranolazine inhibited both inward depolarizing and outward repolarizing currents. The potency (IC₅₀) of drug inhibition of late I_Na ranged between 5 and 21 µmol/L, with a greater potency at more positive voltage-clamp test potentials and higher frequency of depolarization. Although ranolazine inhibited late I_Ca,L with an IC₅₀ of 50 µmol/L, significant inhibition (25% to 30%) occurred within the therapeutic range (2 to 6 µmol/L). The drug weakly inhibited I_Na-Ca (inward sodium-calcium exchange current), peak I_Ca,L, and the slow component of the delayed rectifier potassium current (I_Ks: 17% inhibition at 30 µmol/L and 20% at 900 µmol/L), but produced no effect on the outward rectifier potassium current (I_K1) or the transient outward potassium current (I_to).

View larger version (27K): [in this window] [in a new window]   Figure 1. Effect of ranolazine on rapidly activating component of delayed rectifier current (IKr, left) and inward rectifier current (IK1, right) in canine left ventricular myocytes. Top panels illustrate voltage protocol and representative current traces. Bottom panels are concentration-response relationships. Data are presented as mean±SEM (n=5 to 8).

View larger version (24K): [in this window] [in a new window]   Figure 2. Effect of ranolazine on sodium-calcium exchange current (INa-Ca, left), peak and late calcium channel current (ICa and late ICa, middle), and late sodium current (late INa, right). Top panels show voltage protocols used and representative current traces. Bottom panels are concentration-response relationships. Data are presented as mean±SEM (n=3 to 14 as indicated over data points)

View larger version (33K): [in this window] [in a new window]   Figure 3. Summary of concentration-response relationships for effect of ranolazine to inhibit inward and outward ion channel currents in canine ventricular myocytes. Numbers inside parentheses are IC50 values for effect of ranolazine to inhibit rapidly activating delayed rectifier potassium current (IKr), late sodium current (late INa), peak calcium current (ICa), late ICa, and sodium-calcium exchange current (INa-Ca).

Figure 3 shows the superimposed concentration-response curves for all of the currents for which such a relationship could be obtained. The plot highlights the overlap between the inhibition by ranolazine of I_Kr, late I_Na, and late I_Ca at clinically relevant therapeutic concentrations (2 to 6 µmol/L), suggesting that the effect of the drug to block outward repolarizing current, which prolongs action potential duration (APD), is substantially counterbalanced by its effect to inhibit the inward current, which is expected to abbreviate the action potential.

Effect of Ranolazine in Isolated Canine Ventricular Tissues
Ranolazine caused no change in resting membrane potential, action potential amplitude, or overshoot in either midmyocardial (M) or epicardial cells, except at very high concentrations (100 µmol/L), considerably above the plasma concentrations encountered in clinical use (Table 1).

View this table: [in this window] [in a new window]   TABLE 1. Effects of Ranolazine on Phase 0 Amplitude, Resting Membrane Potential, and Overshoot of Action Potential in M Cell and Epicardial Preparations at a BCL of 500 ms

Figure 4 illustrates the effect of ranolazine on the maximal rate of increase of the upstroke (V_max) of the action potential recorded from free-running canine Purkinje fibers. Significant inhibition, presumably because of the effect of ranolazine to block peak I_Na, was observed only at concentrations 50 µmol/L. Similar inhibition was observed in canine ventricular M cells (not shown). Shown in the bottom panel of Figure 4 is the effect of ranolazine on the APD of canine Purkinje fibers. At a basic cycle length (BCL) of 2000 ms, ranolazine produced a concentration-dependent abbreviation of APD that was greater at 50% than at 90% repolarization. At a BCL of 500 ms, the drug produced little change in APD₉₀, but a concentration-dependent depression of the action potential plateau.

View larger version (21K): [in this window] [in a new window]   Figure 4. Concentration-dependent effects of ranolazine on rate of rise of upstroke of a Purkinje fiber action potential (Vmax). A, Superimposed action potentials and corresponding differentiated upstrokes (dV/dt) recorded in absence and presence of ranolazine (1 to 100 µmol/L) (BCL=500 ms). B, Concentration-response relationship of ranolazine’s effect to reduce Vmax. Data are presented as mean±SEM (n=5). C, Concentration-dependent effect of ranolazine on APD at 50% and 90% repolarization (APD50 and APD90). BCL=2000 ms. Values are mean±SEM. *P=0.05 vs control.

The effects of ranolazine on the action potential of canine ventricular M cell and epicardial tissues are illustrated in Figure 5. The drug caused a small concentration-dependent prolongation of APD in epicardium but an abbreviation or biphasic effect in M cell preparations. Thus, ranolazine caused a concentration-dependent reduction of transmural dispersion of APD. Higher concentrations of the drug produced a depression of the plateau of the action potential, probably because of the effect of ranolazine to inhibit I_Ca and late I_Ca. The preferential prolongation of epicardial APD was more apparent at a [K⁺]_o of 2 mmol/L than at 4 mmol/L (Figure 5, right). Early afterdepolarizations (EADs) were not observed at any concentration of ranolazine, not even under bradycardic and hypokalemic conditions known to potentiate the effect of I_Kr blocker to induce EADs.

View larger version (20K): [in this window] [in a new window]   Figure 5. Left, 4 mmol/L [K+]o. Effects of ranolazine on epicardial and M cell action potentials. A, Superimposed transmembrane action potentials recorded under control conditions and after addition of progressively higher concentrations of ranolazine (1 to 100 µmol/L). B, Concentration-response curves for effect of ranolazine on APD (APD50 and APD90). Right, 2 mmol/L [K+]o. Effects of ranolazine on epicardial and M cell action potentials recorded at a pacing cycle length of 2000 ms and [K+]o=2 mmol/L. C, Superimposed transmembrane action potentials recorded in absence and presence of ranolazine (1 to 100 µmol/L). D, Concentration-dependent effect of ranolazine on APD (APD50 and APD90). BCL=2000 ms. Data are presented as mean±SEM.

These concentration- and rate-dependent characteristics of ranolazine distinguish it from other agents that block I_Kr. Whereas selective I_Kr blockers invariably produce a concentration-dependent prolongation of APD that is greater in Purkinje fibers and M cells than in epicardial cells, the multi–ion channel block produced by ranolazine causes a concentration-dependent abbreviation of Purkinje and M cell APD but a slight prolongation of APD of epicardial cells.

Figure 6 illustrates another important distinction between typical I_Kr blockers and ranolazine. E-4031, a highly selective I_Kr blocker, caused a reverse rate-dependent prolongation of APD that is much greater in M cells than in epicardial cells, leading to a bradycardia-dependent accentuation of transmural dispersion of APD (TD-APD), typical of the actions of I_Kr blockers. In contrast, ranolazine produced a largely rate-independent prolongation of APD in epicardium and abbreviation in M cells, leading to a rate-independent reduction of transmural dispersion of APD. The reverse rate-dependent prolongation of APD and accentuation of TD-APD by E-4031 were still more dramatic at a [K⁺]_o of 2 mmol/L (Figure 6, right). In contrast, ranolazine persisted in causing a rate-independent reduction of TD-APD at the lower [K⁺]_o. These results are consistent with the clinical finding that prolongation of QTc by ranolazine, unlike that of pure I_Kr blockers, is not reverse rate dependent.⁷ Thus, although ranolazine modestly prolongs APD and QTc, it is fundamentally different from other I_Kr blockers, which are typically associated with proarrhythmic actions.

View larger version (28K): [in this window] [in a new window]   Figure 6. Rate-dependent effect of ranolazine (10 µmol/L) and E-4031 (1 µmol/L) on APD in canine ventricular M cell and epicardial tissue slices in presence of 4 mmol/L (A and B) and 2 mmol/L (C and D) [K+]o. A and C, Rate-dependence of E-4031 and ranolazine-induced change in APD90 of M and epicardial cells, respectively. B and D, Rate-dependence of drug-induced change in transmural dispersion of APD (TD-APD90). Values are mean±SEM.

Effect of Ranolazine in Canine Left Ventricular Wedge Preparation
Table 2 shows the effect of ranolazine in isolated canine left ventricular wedge preparations. In the presence of 4 mmol/L [K⁺]_o and at a BCL of 2000 ms, ranolazine caused a small concentration-dependent prolongation of epicardial APD and a small biphasic effect in the M region, resulting in a 30-ms QT prolongation at the highest concentration tested (100 µmol/L). It is noteworthy that much of the QT-interval prolongation observed at the higher concentrations of ranolazine is a result of a slowing of conduction secondary to sodium channel inhibition. Transmural dispersion of repolarization (TDR) showed a tendency to diminish, although the decrease was not statistically significant. Under hypokalemic conditions ([K⁺]_o=3 mmol/L), ranolazine produced a much greater prolongation of the QT interval, but TDR showed a similar tendency to decrease.

View this table: [in this window] [in a new window]   TABLE 2. Summary of the Effects of Ranolazine on the Action Potential Duration, QT Interval, and Transmural Dispersion of Repolarization in the Canine Arterially Perfused Left Ventricular Wedge Preparation

Ranolazine did not induce either spontaneous or programmed electrical stimulation–mediated torsade de pointes (TdP) during endocardial or epicardial pacing of the canine left ventricular wedge preparation at any concentration up to 100 µmol/L. TdP did not develop, nor could it be induced, even in the presence of extremely low [K⁺]_o (2 or 3 mmol/L) and high concentrations of ranolazine. In contrast, both spontaneous and stimulation-induced TdP have been shown to develop in the perfused wedge preparation in response to a wide variety of I_Kr blockers.⁸

Neither early nor delayed afterdepolarizations were observed in either tissue or wedge preparations pretreated with any concentration of ranolazine. On the contrary, as illustrated in Figure 7, ranolazine proved to be effective in suppressing EADs in M cell and Purkinje fiber preparations pretreated with other I_Kr blockers, such as d-sotalol. d-Sotalol (100 µmol/L) produced a remarkable prolongation of repolarization and induced EADs in both M cell and Purkinje fiber preparations. Ranolazine caused a concentration-dependent abbreviation of the action potential and abolished the EADs. A similar effect of ranolazine (5 to 20 µmol/L) to suppress EAD activity and abbreviate APD was observed in 4 of 4 M cell and 3 of 3 Purkinje fiber preparations. Moreover, ranolazine was found to be effective in reducing TD-APD, the interval between the peak and end of the T wave (T_peak-T_end) and TDR under long-QT conditions (d-sotalol, moxifloxacin, and sea anemone toxin [ATX]-II) (data not shown).

View larger version (25K): [in this window] [in a new window]   Figure 7. Effect of ranolazine to suppress d-sotalol–induced EADs in M cell and Purkinje fiber preparations. A, Superimposed transmembrane action potentials recorded from a Purkinje fiber preparation in presence of IKr block (100 µmol/L d-sotalol) and after addition of increasing concentrations of ranolazine (5 and 10 µmol/L) in continued presence of d-sotalol. [K+]o=3 mmol/L, BCL=8000 ms, B, Superimposed transmembrane action potentials recorded from an M cell preparation under control conditions, in presence of IKr block (100 µmol/L d-sotalol), and after increasing concentrations of ranolazine (5, 10, and 20 µmol/L) in continued presence of d-sotalol. BCL=2000 ms.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The effects of ranolazine on cardiac ion currents at concentrations within the therapeutic range (ie, 2 to 6 µmol/L) include inhibition of I_Kr, late I_Na, and late I_Ca,L. Inhibition of I_Kr by ranolazine prolongs APD, and its effect to inhibit late I_Na and late I_Ca,L abbreviates APD. The net effect and clinical consequence of inhibition of these ion channel currents is a modest increase in the mean QTc interval over the therapeutic range. The drug differs significantly from other agents that block I_Kr and induce TdP. Ranolazine-induced prolongation of the APD is rate independent (ie, does not display reverse rate-dependent prolongation of APD) and is not associated with EADs, triggered activity, an increase in spatial dispersion of repolarization, or polymorphic ventricular tachycardia. Indeed, rather than displaying arrhythmogenic activity, ranolazine, via its actions to suppress EADs and reduce TDR, possesses significant antiarrhythmic activity, acting to suppress the arrhythmogenic effects induced by a variety of other QT-prolonging drugs.

Drugs with QT-prolonging properties have attracted considerable attention in recent years because of their proclivity to induce life-threatening cardiac arrhythmias, such as TdP.^9–11 More than 50 commercially available or investigational noncardiovascular and 20 cardiovascular nonantiarrhythmic drugs have been shown or are suspected to have proarrhythmic effects.

The mechanisms underlying TdP have long been a matter of debate. Recent studies have identified dispersion of repolarization secondary to accentuation of electrical heterogeneities intrinsic to ventricular myocardium as the substrate and EADs as the trigger for the development of TdP.^8,10,12–15

Ventricular myocardium is composed of at least 3 electrophysiologically distinct cell types: epicardial, M, and endocardial. M cells are distinguished by having action potentials that prolong disproportionately relative to the action potentials of other ventricular myocardial cell types in response to a slowing of rate and/or in response to many QT-prolonging drugs.^16–18 The ionic bases for these features include the presence of a smaller slowly activating delayed rectifier current (I_Ks),¹⁹ a larger late I_Na,²⁰ and I_Na-Ca.²¹ I_Kr and I_K1 are similar in the 3 transmural cell types. M cells, like Purkinje fibers, develop EADs in response to agents and pathophysiological conditions that reduce the repolarization reserve of the ventricular myocardium. Epicardial and endocardial cells generally do not.

Most drugs that prolong the QT interval accentuate the normal transmural heterogeneity of final ventricular repolarization by causing a preferential prolongation of the action potential of M cells. I_Kr blockers, including d-sotalol, almokalant, E-4031, moxifloxacin, and erythromycin augment transmural dispersion of repolarization as a consequence. These agents cause relatively little prolongation of the APD of epicardial and endocardial cells, because these cell types possess a much more prominent I_Ks than the M cell. A similar preferential prolongation of the M cell APD is seen with agents that increase calcium current (I_Ca), such as Bay K 8644, as well as with agents that increase late I_Na, such as ATX-II, anthopleurin-A, and DPI 201-106. An exception to this rule applies to agents that block I_Ks, which cause a similar percentage of APD prolongation in the 3 transmural cell types.

A more complex electrophysiological effect is observed with drugs affecting 2 or more ion channels, such as amiodarone, sodium pentobarbital, quinidine, cisapride, and azimilide. Amiodarone is a potent antiarrhythmic agent used in the management of both atrial and ventricular arrhythmias. In addition to its ß-blocking properties, amiodarone is known to block late I_Na, I_Ca, I_Kr, and I_Ks. The efficacy of the amiodarone and its low incidence of proarrhythmia relative to other agents with class III actions are attributable to this complex multichannel inhibition.²² When administered chronically, amiodarone increases QT without augmenting spatial dispersion of repolarization, unlike other I_Kr blockers.^23–25 In some cases, transmural dispersion of repolarization is reduced.²³ Chronic amiodarone therapy can also suppress the effect of other I_Kr blockers, like d-sotalol, to increase TDR or induce EADs.²³ Thus, chronic amiodarone alters the cellular electrophysiology of ventricular myocardium so as to reduce TDR and suppress EADs, especially under conditions in which they are accentuated. The drug’s potent inhibition of late I_Na is thought to play a key role.

The multichannel inhibition, particularly the ability to potently block late I_Na, has been suggested to underlie the effect of I_Kr blockers to prolong QT without creating the substrate or trigger for the development of TdP. Indeed, this feature could contribute to the suppression of EADs and reduction of spatial dispersion of repolarization, the substrate and trigger for TdP. This is the case for amiodarone and sodium pentobarbital, as well as for high concentrations of quinidine and cisapride.^24,26–28 Our data suggest that ranolazine fits this pharmacological profile as well. Like amiodarone and sodium pentobarbital, ranolazine produces a preferential prolongation of epicardial APD₉₀, leading to a reduction in transmural dispersion of repolarization. The opposite effects of ranolazine on M cells and Purkinje fibers to that of epicardial APD is most likely because of the more prominent late I_Na in the M cell and Purkinje fiber than in epicardial cells.²⁰ Ranolazine is among the most potent late I_Na blockers reported. It causes a decrease in net inward current in the M cells and Purkinje fiber but a decrease in net outward current in epicardium. The effect of ranolazine to block late I_Na and late I_Ca most likely underlies its effect to suppress EAD activity. Thus, unlike other I_Kr blockers, ranolazine does not lead to the development of TdP, either spontaneous or stimulation induced. Of note, ranolazine has recently been evaluated in an anesthetized dog model with acute complete atrioventricular block, a model susceptible to drug-induced polymorphic ventricular tachycardia. At doses that prolonged the QT interval by approximately 5% to 11% above control, ranolazine did not cause spontaneous TdP or TdP facilitated by an intravenous bolus of phenylephrine (which increases susceptibility to TdP) in 5 dogs, whereas sotalol induced TdP in all 5 dogs under these conditions.²⁹ Recent studies involving isolated guinea pig and rabbit hearts have also reported failure of ranolazine to induce TdP but its effectiveness to suppress TdP induced by selective I_Kr blockers (E-4031) and agents that augment late I_Na (ATX-II).²⁹

In summary, the available data suggest that ranolazine, in addition to its antianginal actions, may possess important antiarrhythmic activity.

	Acknowledgments

 
This study was supported by grant HL-47678 from the National Heart, Lung, and Blood Institute (Dr Antzelevitch) and grants from the American Heart Association (Drs Burashnikov, Fish, and Antzelevitch), CV Therapeutics (Dr Antzelevitch), and the NY State and Florida Grand Lodges of the Free and Accepted Masons.

	Footnotes

 
The online-only Data Supplement, which contains information about the Methods used in the study, can be found with this article at http://www.circulationaha.org.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291: 309–316.[Abstract/Free Full Text]

2. Louis AA, Manousos IR, Coletta AP, et al. Clinical trials update: the Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. Eur J Heart Fail. 2002; 4: 111–116.[CrossRef][Medline] [Order article via Infotrieve]

3. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. 1999; 84: 46–50.[Medline] [Order article via Infotrieve]

4. Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. 2002; 91: 278–280.[Abstract/Free Full Text]

5. Liu DW, Gintant GA, Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res. 1993; 72: 671–687.[Abstract/Free Full Text]

6. Zygmunt AC, Goodrow RJ, Antzelevitch C. Sodium effects on 4-aminopyridine-sensitive transient outward current in canine ventricular cells. Am J Physiol. 1997; 272: H1–H11.[Medline] [Order article via Infotrieve]

7. Okada Y, Ogawa S, Sadanaga T, et al. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J Am Coll Cardiol. 1996; 27: 84–89.[Abstract]

8. Belardinelli L, Antzelevitch C, Vos M. Potential predictors of drug-induced torsade de pointes: early afterdepolarizations, ectopic beats and increased dispersion of ventricular repolarization. Trends Pharmacol Sci. 2003; 24: 619–625.[CrossRef][Medline] [Order article via Infotrieve]

9. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non–anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000; 47: 219–233.[Free Full Text]

10. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002; 17: 43–51.[CrossRef][Medline] [Order article via Infotrieve]

11. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis. 2001; 43: 1–45.[Medline] [Order article via Infotrieve]

12. El-Sherif N. Polymorphic ventricular tachycardia and torsades de pointes: beyond etymology. J Cardiovasc Electrophysiol. 2001; 12: 695–696.[CrossRef][Medline] [Order article via Infotrieve]

13. Kozhevnikov DO, Yamamoto K, Robotis D, et al. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns. Circulation. 2002; 105: 1128–1134.[Abstract/Free Full Text]

14. Akar FG, Rosenbaum DS. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res. 2003; 93: 638–645.[Abstract/Free Full Text]

15. Vos MA, van Opstal JM, Leunissen JD, et al. Electrophysiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias. Pharmacol Ther. 2001; 92: 109–122.[CrossRef][Medline] [Order article via Infotrieve]

16. Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle: the M cell. Circ Res. 1991; 68: 1729–1741.[Abstract/Free Full Text]

17. Antzelevitch C, Sicouri S, Litovsky SH, et al. Heterogeneity within the ventricular wall: electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ Res. 1991; 69: 1427–1449.[Free Full Text]

18. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiologic properties of epicardium, midmyocardium and endocardium: in vitro and in vivo correlations. Circulation. 1996; 94: 1981–1988.[Abstract/Free Full Text]

19. Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (I_Kr and I_Ks) in canine ventricular epicardial, midmyocardial and endocardial myocytes: a weaker I_Ks contributes to the longer action potential of the M cell. Circ Res. 1995; 76: 351–365.[Abstract/Free Full Text]

20. Zygmunt AC, Eddlestone GT, Thomas GP, et al. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol. 2001; 281: H689–H697.

21. Zygmunt AC, Goodrow RJ, Antzelevitch C. I_Na-Ca contributes to electrical heterogeneity within the canine ventricle. Am J Physiol. 2000; 278: H1671–H1678.

22. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994; 121: 529–535.[Abstract/Free Full Text]

23. Sicouri S, Moro S, Litovsky SH, et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 1997; 8: 1269–1279.[Medline] [Order article via Infotrieve]

24. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001; 104: 2722–2727.[Abstract/Free Full Text]

25. Cui G, Sen L, Sager PT, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol. 1994; 74: 896–900.[CrossRef][Medline] [Order article via Infotrieve]

26. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999; 10: 1124–1152.[Medline] [Order article via Infotrieve]

27. Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation. 2003; 108: 1027–1033.[Abstract/Free Full Text]

28. Shimizu W, McMahon B, Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsade de pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol. 1999; 10: 156–164.

29. CV Therapeutics. Ranexa (Ranolazine) FDA Review Documents. NDA 21–256 December 09, 2003.

This article has been cited by other articles:

				H. Hwang, J. M. Arcidi Jr, S. L. Hale, B. Z. Simkhovich, L. Belardinelli, A. K. Dhalla, J. C. Shryock, and R. A. Kloner Ranolazine as an Adjunct to Cardioplegia: A Potential New Therapeutic Application Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 125 - 133. [Abstract] [PDF]

				S. R. Wilson, B. M. Scirica, E. Braunwald, S. A. Murphy, E. Karwatowska-Prokopczuk, J. L. Buros, B. R. Chaitman, and D. A. Morrow Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1510 - 1516. [Abstract] [Full Text] [PDF]

				D. A. Morrow, B. M. Scirica, B. R. Chaitman, D. K. McGuire, S. A. Murphy, E. Karwatowska-Prokopczuk, C. H. McCabe, E. Braunwald, and for the MERLIN-TIMI 36 Investigators Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial Circulation, April 21, 2009; 119(15): 2032 - 2039. [Abstract] [Full Text] [PDF]

				B. F. McBride The Emerging Role of Antiarrhythmic Compounds With Atrial Selectivity in the Management of Atrial Fibrillation J. Clin. Pharmacol., March 1, 2009; 49(3): 258 - 267. [Abstract] [Full Text] [PDF]

				J.-P. Couderc, S. Kaab, M. Hinterseer, S. McNitt, X. Xia, A. Fossa, B. M. Beckmann, S. Polonsky, and W. Zareba Baseline Values and Sotalol-Induced Changes of Ventricular Repolarization Duration, Heterogeneity, and Instability in Patients With a History of Drug-Induced Torsades de Pointes J. Clin. Pharmacol., January 1, 2009; 49(1): 6 - 16. [Abstract] [Full Text] [PDF]

				W.-Q. Wang, C. Robertson, A. K. Dhalla, and L. Belardinelli Antitorsadogenic Effects of ({+/-})-N-(2,6-Dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (Ranolazine) in Anesthetized Rabbits J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 875 - 881. [Abstract] [Full Text] [PDF]

				I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF]

				Y. Song, J. C. Shryock, and L. Belardinelli An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2031 - H2039. [Abstract] [Full Text] [PDF]

				L. L. Eckhardt, T. C. Teelin, and C. T. January Is ranolazine an antiarrhythmic drug? Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H1989 - H1991. [Full Text] [PDF]

				B. M. Scirica, D. A. Morrow, H. Hod, S. A. Murphy, L. Belardinelli, C. M. Hedgepeth, P. Molhoek, F. W.A. Verheugt, B. J. Gersh, C. H. McCabe, et al. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial Circulation, October 9, 2007; 116(15): 1647 - 1652. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2024 - H2038. [Abstract] [Full Text] [PDF]

				A. Burashnikov, J. M. Di Diego, A. C. Zygmunt, L. Belardinelli, and C. Antzelevitch Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine Circulation, September 25, 2007; 116(13): 1449 - 1457. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes Europace, September 1, 2007; 9(suppl_4): iv4 - iv15. [Abstract] [Full Text] [PDF]

				K. Ahmad and P. Dorian Drug-induced QT prolongation and proarrhythmia: an inevitable link? Europace, September 1, 2007; 9(suppl_4): iv16 - iv22. [Abstract] [Full Text] [PDF]

				B. Darpo Detection and reporting of drug-induced proarrhythmias: room for improvement Europace, September 1, 2007; 9(suppl_4): iv23 - iv36. [Abstract] [Full Text] [PDF]

				E. Shantsila, T. Watson, and G. Y. Lip Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias Europace, September 1, 2007; 9(suppl_4): iv37 - iv44. [Abstract] [Full Text] [PDF]

				J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]

				I. N. Sabir, M. J. Killeen, C. A. Goddard, G. Thomas, S. Gray, A. A. Grace, and C. L.-H. Huang Transient alterations in transmural repolarization gradients and arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts J. Physiol., May 15, 2007; 581(1): 277 - 289. [Abstract] [Full Text] [PDF]

				D. A. Morrow, B. M. Scirica, E. Karwatowska-Prokopczuk, S. A. Murphy, A. Budaj, S. Varshavsky, A. A. Wolff, A. Skene, C. H. McCabe, E. Braunwald, et al. Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial JAMA, April 25, 2007; 297(16): 1775 - 1783. [Abstract] [Full Text] [PDF]

				M. J. Koren, M. R. Crager, and M. Sweeney Long-Term Safety of a Novel Antianginal Agent in Patients With Severe Chronic Stable Angina: The Ranolazine Open Label Experience (ROLE) J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1027 - 1034. [Abstract] [Full Text] [PDF]

				K. Zerumsky and B. F. McBride Ranolazine in the management of chronic stable angina Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2331 - 2338. [Abstract] [Full Text] [PDF]

				P. H. Stone, N. A. Gratsiansky, A. Blokhin, I-Z. Huang, L. Meng, and for the ERICA Investigators Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial J. Am. Coll. Cardiol., August 1, 2006; 48(3): 566 - 575. [Abstract] [Full Text] [PDF]

				Y. Song, J. C. Shryock, S. Wagner, L. S. Maier, and L. Belardinelli Blocking Late Sodium Current Reduces Hydrogen Peroxide-Induced Arrhythmogenic Activity and Contractile Dysfunction J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 214 - 222. [Abstract] [Full Text] [PDF]

				S. L. Hale, J. A. Leeka, and R. A. Kloner Improved Left Ventricular Function and Reduced Necrosis after Myocardial Ischemia/Reperfusion in Rabbits Treated with Ranolazine, an Inhibitor of the Late Sodium Channel J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 418 - 423. [Abstract] [Full Text] [PDF]

				L Belardinelli, J C Shryock, and H Fraser Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine Heart, July 1, 2006; 92(suppl_4): iv6 - iv14. [Abstract] [Full Text] [PDF]

				C. Marx and M. Sweeney Mechanism of action of ranolazine. Arch Intern Med, June 26, 2006; 166(12): 1325 - 1326. [Full Text] [PDF]

				B. R. Chaitman Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions Circulation, May 23, 2006; 113(20): 2462 - 2472. [Full Text] [PDF]

				L. Wu, J. C. Shryock, Y. Song, and L. Belardinelli An Increase in Late Sodium Current Potentiates the Proarrhythmic Activities of Low-Risk QT-Prolonging Drugs in Female Rabbit Hearts J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 718 - 726. [Abstract] [Full Text] [PDF]

				L. Belardinelli, J. C. Shryock, and H. Fraser The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction Eur. Heart J. Suppl., February 1, 2006; 8(suppl_A): A10 - A13. [Abstract] [Full Text] [PDF]

				J.-P. Bassand Clinical implications of inhibition of the late sodium current: ranolazine Eur. Heart J. Suppl., February 1, 2006; 8(suppl_A): A14 - A19. [Abstract] [Full Text] [PDF]

				P. A. Poole-Wilson, A. Jacques, and A. Lyon Treatment of angina: a commentary on new therapeutic approaches Eur. Heart J. Suppl., February 1, 2006; 8(suppl_A): A20 - A25. [Abstract] [Full Text] [PDF]

				D. A. Morrow and M. M. Givertz Modulation of Myocardial Energetics: Emerging Evidence for a Therapeutic Target in Cardiovascular Disease Circulation, November 22, 2005; 112(21): 3218 - 3221. [Full Text] [PDF]

				S. Viskin and U. Rosovski The degree of potassium channel blockade and the risk of torsade de pointes: the truth, nothing but the truth, but not the whole truth Eur. Heart J., March 2, 2005; 26(6): 536 - 537. [Full Text] [PDF]

				C. Antzelevitch Cardiac repolarization. The long and short of it Europace, January 1, 2005; 7(s2): S3 - S9. [Abstract] [Full Text] [PDF]

				C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 110/8/904    most recent 01.CIR.0000139333.83620.5Dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antzelevitch, C. Articles by Thomas, G. Search for Related Content PubMed PubMed Citation Articles by Antzelevitch, C. Articles by Thomas, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETANILIDE CALCIUM COMPOUNDS CALCIUM, ELEMENTAL POTASSIUM SODIUM Related Collections Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs